AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03533634 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open Reduction Internal Fixation superior plate
Description: 3.5mm superior reconstruction plate
Study NCT03533634 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open Reduction Internal Fixation anteroinferior plate
Description: 3.5mm anteroinferior reconstruction plate
Study NCT03075904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN1830
Description: Administered via IV infusion.
Study NCT03301727 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive-Behavioural Therapy for Insomnia (CBT-I)
Description: Cognitive-Behavioural Therapy for Insomnia (CBT-I) is an evidence-based psycho-therapeutic intervention, combining cognitive and behavioural principles to provide psycho-education concerning contributing thoughts to sleep problem maintenance, and behavioural technique instruction to reduce sleep onset latency and promote effective sleep maintenance.
Study NCT03301727 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Cognitive-Behavioural Therapy for Insomnia (CBT-I)
Description: Cognitive-Behavioural Therapy for Insomnia (CBT-I) is an evidence-based psycho-therapeutic intervention, combining cognitive and behavioural principles to provide psycho-education concerning contributing thoughts to sleep problem maintenance, and behavioural technique instruction to reduce sleep onset latency and promote effective sleep maintenance.
Study NCT04929093 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Novel dose adjustment of Alutard SQ
Description: novel dose adjustment schedule means directly reaching dose of Vial 4, 10,000 SQ
Study NCT04929093 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: conventional dose adjustment of Alutard SQ
Description: conventional dose adjustment schedule means restarting from dose of Vial 1, 10 SQ
Study NCT04929093 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Routine continuous cluster of Alutard SQ
Description: Patient receiving continuous cluster SCIT for DM during the same period
Study NCT03836508 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medium cut-off
Description: All the dialysis sessions in this arm will be performed with the medium cut-off membrane (MCO) manufactured by Baxter International Corp. membrane for three months. This membrane will exclusively be used in hemodialysis. After third month, all patients will be switched to high-flux membrane manufactured by Fresenius.~Modalities of hemodialysis : Blood flow: 300-400 mL/min; Dialysate flow: 500-800 mL/min
Study NCT03836508 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High-Flux
Description: All the dialysis sessions in this arm will be performed with the high-flux membrane manufactured by Fresenius for three months. This membrane will exclusively be used in hemodialysis. After third month, all patients will be switched to MCO manufactured by Baxter International Corp.~Modalities of hemodialysis : Blood flow: 300-400 mL/min; Dialysate flow: 500-800 mL/min
Study NCT02294110 — intervention group
Intervention type: OTHER
Intervention: spinal anesthesia
Description: non diabetes mellitus
Study NCT00988546 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computer based template for exam documentation
Description: exam documentation performed using computer based template
Study NCT00988546 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Dictation for exam documentation
Description: exam documentation performed using dictation, the standard practice
Study NCT02024035 — intervention group
Intervention type: RADIATION
Intervention: Radiotherapy
Study NCT02266602 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Intraoperative Radiation Therapy
Description: Intraoperative radiation therapy at the time of partial mastectomy in early stage breast cancer
Study NCT03195465 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dark Chocolate
Description: Dark Chocolate bars with 70% cacao and 30% organic cane sugar where 4 squares of the dark chocolate will be administered twice daily between the hours of 6 a.m. and 6 p.m. daily for four weeks.
Study NCT03097861 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lubiprostone
Description: 24 mcg administered orally BID
Study NCT03097861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lubiprostone
Description: 24 mcg administered orally BID
Study NCT03097861 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 24 mcg administered orally BID
Study NCT01382485 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RIA harvesting group
Description: Subjects allocated to the RIA group will have the graft harvested in a standardized fashion using the technique described by Quintero et al. Briefly, the RIA device is a single-pass reamer that is connected to an aspirator and irrigator, allowing simultaneous reaming, irrigation, and aspiration of the contents of the femoral canal. RIA head size and tube length will be chosen based on preoperative templating of anteroposterior and lateral radiographs of the donor femur (a head size of 2mm larger than the inner cortical diameter at the isthmus of the femur will be selected). Fluoroscopic imaging will be used to confirm guidewire positioning and avoid eccentric reaming. Bone graft will be harvested from the central femoral canal and from each femoral condyle in 3 separate passes.
Study NCT01382485 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: AICBG harvesting group
Description: Iliac crest bone graft will be harvested from the anterior iliac crest through an incision beginning 2cm posterior to the anterior superior iliac spine and carried posteriorly. A window will be made in the iliac crest and a curette will subsequently be used to harvest the cancellous bone. The incision will be closed in 3 layers. The infiltration of local anaesthetic will be at the discretion of the surgeon.
Study NCT03560258 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: p24CE1/2 pDNA vaccine
Description: 4 mg administered by one injection/electroporation
Study NCT03560258 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: p24CE1/2 pDNA vaccine admixed with full-length p55^gag pDNA vaccine
Description: 2 mg p24CE1/2 pDNA admixed with 2 mg full-length p55\^gag pDNA administered by one injection/electroporation
Study NCT03251261 — intervention group
Intervention type: DEVICE
Intervention: illumigene CMV assay, illumipro-10
Description: CMV assay for detection of CMV
Study NCT03560258 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Full-length p55^gag pDNA vaccine
Description: 4 mg full-length p55\^gag pDNA vaccine administered by one injection/electroporation
Study NCT03560258 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 mL placebo administered by one injection/electroporation
Study NCT01153269 — intervention group
Intervention type: DRUG
Intervention: Lopinavir/Ritonavir (Kaletra)
Description: 3 capsules 2xdaily or 2 tablets 2xdaily Kaletra
Study NCT03847467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2'-Fucosyllactose
Description: Human milk oligosaccharide prebiotic dietary supplement
Study NCT03847467 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dextrose
Study NCT02715817 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Rehabilitation
Description: It is the use of the NW games for rehabilitation of balance and gaite in post-stroke patients.
Study NCT02715817 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional therapeutic exercises
Description: It is the use of the conventional therapeutic exercises for rehabilitation of balance and gait in post-stroke patients.
Study NCT02715817 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Rehabilitation and Conventional Therapeutic Exercise
Description: It is the use of the conventional exercises and of the NW for rehabilitation of balance and gait in post-stroke patients.
Study NCT04714801 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adipose derived mesenchymal stromal cells
Description: Intravenous infusion of cells
Study NCT04714801 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Intravenous infusion of saline
Study NCT04596137 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: İnfant pain management
Description: Kangaroo mother care was applied to the infants during heel prick. With kangaroo mother care, the pain of infants was reduced.
Study NCT01021774 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anal fistula treatment
Description: A comparison of collagen plug vs advancement flap surgery
Study NCT00810758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04878691 3mg
Description: Oral solution, 3mg, twice weekly, 2 weeks
Study NCT00810758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04878691 6mg
Description: Oral solution, 6mg, twice weekly, 2 weeks
Study NCT00810758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04878691 9mg
Description: Oral solution, 9mg, twice weekly, 2 weeks
Study NCT01930630 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extraesophageal saline injection (ESI)
Description: The patients with advanced ESCC are to undergo extraesophageal injection of 15ml saline preoperatively and subsequently detected by EUS to confirm whether saline separates esophagus from adjacent organs.
Study NCT03180671 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Deprogramer Sliding Guide
Description: Use of the intraoral device.
Study NCT03180671 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Deprogrammer Dawson B-Splint
Description: Use of the intraoral device.
Study NCT03180671 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Deprogrammer Kois
Description: Use of the intraoral device.
Study NCT00744328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal Estradiol
Description: Estradiol patch ranging in dose from 50 to 200 mcg/day
Study NCT00744328 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertraline
Description: Sertraline dose will range from 50 - 200 mg/day
Study NCT00744328 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo patches and pills that are identical to transdermal estradiol and oral sertraline, respectively, will be used.
Study NCT00744328 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo patches and pills that are identical to transdermal estradiol and oral sertraline, respectively, will be used.
Study NCT00744328 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo patches and pills that are identical to transdermal estradiol and oral sertraline, respectively, will be used.
Study NCT04785664 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community-based pro-Active Monitoring Program
Description: The Intervention provides phone monitoring addressed to all the clients and home visits tailored to the individual needs. Moreover, it activates other formal or informal care resources based on the needs of the patients reported in the Individualized Care Plan (ICP) which derives from the assessment of multidimensional frailty. The main peculiarity of the program is that the operators identify the main problem of the client and try to track down the best solution in agreement with the client. It can be a health or social intervention or a different kind. Interventions may include assistance to make clients' houses safer thereby reducing risk factors for falls or reviewing the therapeutic scheme to improve patient adherence to the treatment in collaboration with the GP.
Study NCT02093676 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: experimental protocol treatment The New Authority
Study NCT02430701 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Irreversible electroporation (IRE)
Description: Irreversible Electroportion For Unresectable Esophageal Neoplasms guide with ultrasound or/and CT.
Study NCT02430701 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NanoKnife
Study NCT02428244 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: Motivational Interviewing coupled with education will be provided to help participants understand the risks associated with smoking and their fracture care. They will be referred to the quitline.
Study NCT02428244 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing + Follow-up
Description: Motivational Interviewing coupled with education will be provided to help participants understand the risks associated with smoking and their fracture care. They will be referred to the quitline.~In this intervention, the participants will receive additional motivational interviewing sessions at 2 weeks, 6 weeks, 3 months and 6 months.
Study NCT04564950 — intervention group
Intervention type: OTHER
Intervention: Observation of serum and salivary Galectin-3 levels
Description: Observation of serum and salivary Galectin-3 levels and correlation with periodontal indices
Study NCT02200029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ademetionine IV+tablet
Description: IV ademetionine (500 mg/vial) for 2 weeks followed by oral ademetionine (500 mg/tablet, 2 in the morning and 1 before dinner) for 6 weeks
Study NCT02200029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ademetionine tablet
Description: oral ademetionine (500 mg/tablet, 2 in the morning and 1 before dinner) for 8 weeks
Study NCT00655083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nepadutant
Description: 0.1 mg/Kg as one single oral dose divided in three age strata (from 6 to 24 weeks old)
Study NCT00655083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nepadutant
Description: 0.5 mg/Kg as one single oral dose divided in three age strata (from 6 to 24 weeks old)
Study NCT00722488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN4924
Description: Intravenous dose 100 mg/m2 on a Days 1,4,8,11 schedule within a 21-day treatment cycle. Treatment may continue until disease progression or unacceptable toxicity develops.
Study NCT02541799 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Audio-visual telemedicine
Description: Participants in an emergency department will have their care delivered using telemedicine, then they will be approached for a study by a study investigator using the same telemedicine link
Study NCT02541799 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Participants in an emergency department will have their care delivered in person, then they will be approached by a study investigator face-to-face.
Study NCT03609671 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard of Care + Experimental Individualized Therapy
Description: Participants will receive standard of care plus supportive psychotherapy for a one hour, weekly, during the time they are undergoing neoadjuvant treatments.
Study NCT03609671 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control: Standard of Care
Description: Participants will undergo standard of care only (no Intervention/no individualized therapy) .
Study NCT00009789 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: accelerated conformational radiotherapy
Study NCT01590121 — intervention group
Intervention type: OTHER
Intervention: Aeroplane flight in the past- no active intervention for study
Description: Aeroplane flight(s) previously taken by study participants
Study NCT01590121 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Flight by aeroplane (previous)
Study NCT02683057 — intervention group
Intervention type: OTHER
Intervention: International Physical Activity Questionnaire (IPAQ)
Description: all candidates for sperm donors clinic IVI IVI Bilbao and Valencia were will provide the international physical activity questionnaire (IPAQ) attached to analyze the total physical activity. This will be self-completed questionnaire beforeSperm donation. (Appendix 1) Age, snuff, weight, BMI, alcohol, drug use and the type of sport that practices will be analyzed: Additionally a tab for each donor collecting the existence of associated factors be drawn. (Appendix 2)
Study NCT01183208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intervention A
Description: A single dose of 3 mg will consist of 3 sprays of the 1 mg strength spray applied topically to cervix (1 spray) and vaginal fornices (2 sprays)
Study NCT01183208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intervention B
Description: A single dose of 30 mg will consist of 3 sprays of the 10 mg strength spray applied topically to cervix (1 spray) and vaginal fornices (2 sprays)
Study NCT01183208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intervention C
Description: A single dose of 150 mg will consist of 15 sprays of the 10 mg strength spray applied topically to cervix (5 sprays) and vaginal fornices (10 sprays)
Study NCT02006121 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apomorphine hydrochloride
Description: Apomorphine hydrochloride 5 mg/ml solution for infusion in pre-filled syringe
Study NCT02006121 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sodium chloride 9 mg/ml
Study NCT01183208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intervention D
Description: A dose of placebo will consist of 3 sprays of the placebo spray applied topically to cervix (1 spray) and vaginal fornices (2 sprays)
Study NCT01183208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intervention E
Description: A dose of placebo will consist of 15 sprays of the placebo spray applied topically to cervix (5 sprays) and vaginal fornices (10 sprays)
Study NCT04410120 — intervention group
Intervention type: OTHER
Intervention: Interview
Description: Semi-structured 45 minute interviews regarding impact of asthma attacks
Study NCT00815035 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peanut OIT
Description: Peanut flour that is orally ingested in a graded fashion.
Study NCT00815035 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oat flour used as a placebo that is orally ingested a graded fashion
Study NCT04649827 — intervention group
Intervention type: OTHER
Intervention: Clinical Observation
Description: This is an observational study, so there are no interventions. Investigators will collect data about demographics, comorbidities, medications, and other risk factors such as the severity of disease at admission, need for advanced life support, need for invasive mechanical ventilation and main outcomes during hospitalization.
Study NCT02672501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-CD19-CAR-T cells
Description: a 2nd CAR, CD19 as target protein, 4-1BB as co- stimulator, and optimized the spatial conformation by a suitable hinge \& transmembrane domain sequences
Study NCT02059668 — intervention group
Intervention type: BIOLOGICAL
Intervention: Biomarker analyses head & neck cancer tissue, blood specimen
Description: For biomarker analyses, tumor tissues from previous biopsies and surgery and blood specimens taken during treatment at the treating institution will be used.
Study NCT03315286 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SHADE Ultraviolet Sensor
Description: Patients will wear device for 6 months in addition to their own method of photo-protection.
Study NCT03315286 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard of care counseling
Description: Patients will use their own method of photo-protection
Study NCT03315286 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care counseling
Description: Patients will use their own method of photo-protection
Study NCT01641497 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 3D conformational radiation
Description: 25 \* 1.8 Gy in 5 weeks (=45 Gy)
Study NCT01641497 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT
Description: 25 \* 1.8 Gy in 5 weeks (=45 Gy)
Study NCT00808639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: intravenously 30mg/m2 over 30 minutes
Study NCT00808639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: intravenously 30mg/ms over 15 minutes
Study NCT00808639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinblastine
Description: intravenously 3mg/m2 over 30 minutes
Study NCT00808639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: intravenously 70mg/m2 in 1 liter NS with 12.5gm Mannitol over 2 hours after vinblastine completion
Study NCT00808639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Given subcutaneously 24 hours after last chemotherapy dose
Study NCT00972556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gray Mineral Trioxide Aggregate (GMTA)
Description: Once hemorrhage from the pulp chamber is under control using direct pressure of a sterile cotton pellet, pulp stumps are covered with a MTA paste, obtained by mixing 0.2g GMTA powder with sterile water in a powder to liquid ratio of 3:1 in weight. The GMTA will be then immediately covered with a zinc-oxide eugenol base (IRM) material.